Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis

British Journal of Pharmacology

Volumn 140, Issue 4, 2003, Pages 620-626

  Von Degenfeld, Georges ^a   Banfi, Andrea ^a   Springer, Matthew L ^a   Blau, Helen M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Arteriogenesis; Gene transfer; Hemangioma; Maturation; Myoblast; Pericytes; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CONFERENCE PAPER; GENE DELIVERY SYSTEM; GENE TRANSFER; GROWTH STIMULATION; HUMAN; MOLECULAR DYNAMICS; MUSCLE BLOOD FLOW; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE;

ARTERIES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MYOBLASTS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0242661024     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705492     Document Type: Conference Paper

References (57)

1. ABO-AUDA, W. & BENZA, R.L. (2003). Therapeutic angiogenesis: review of current concepts and future directions. J. Heart Lung Transplant. 22, 370-382.
2. AUTIERO, M., WALTENBERGER, J., COMMUNI, D., KRANZ, A., MOONS, L., LAMBRECHTS, D., KROLL, J., PLAISANCE, S., DEMOL, M., BONO, F., KLICHE, S., FELLBRICH, G., BALLMER-HOFER, K., MAGLIONE, D., MAYR-BEYRLE, U., DEWERCHIN, M., DOMBROWSKI, S., STANIMIROVIC, D., VAN HUMMELEN, P., DEHIO, C., HICKLIN, D.J., PERSICO, G., HERBERT, J.M., SHIBUYA, M., COLLEN, D., CONWAY, E.M. & CARMELIET, P. (2003). Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med., 9, 936-943.
3. BANFI, A., SPRINGER, M.L. & BLAU, H.M. (2002). Myoblast-mediated gene transfer for therapeutic angiogenesis. Methods Enzymol., 346, 145-157.
4. BARLEON, B., SOZZANI, S., ZHOU, D., WEICH, H.A., MANTOVANI, A. & MARME, D. (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood, 87, 3336-3343.
5. BENJAMIN, L.E., GOLIJANIN, D., ITIN, A., PODE, D. & KESHET, E. (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest., 103, 159-165.
6. BENJAMIN, L.E., HEMO, I. & KESHET, E. (1998). A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development, 125, 1591-1598.
7. BERGERS, G., BREKKEN, R., McMAHON, G., VU, T.H., ITOH, T., TAMAKI, K., TANZAWA, K., THORPE, P., ITOHARA, S., WERB, Z. & HANAHAN, D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. cell Biol., 2, 737-744.
8. BERGERS, G., SONG, S., MEYER-MORSE, N., BERGSLAND, E. & HANAHAN, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest., 111, 1287-1295.
9. BLANCO-BOSE, W.E., YAO, C.C., KRAMER, R.H. & BLAU, H.M. (2001). Purification of mouse primary myoblasts based on alpha 7 integrin expression. Exp. Cell Res., 265, 212-220.
10. BLAU, H.M. & BANFI, A. (2001). The well-tempered vessel. Nat. Med., 7, 532-534.
11. BLAU, H.M. & ROSSI, F.M. (1999). Tet B or not tet B: advances in tetracycline-inducible gene expression. Proc. Natl. Acad. Sci. U.S.A., 96, 797-799.
12. CAO, R., BRAKENHIELM, E., PAWLIUK, R., WARIARO, D., POST, M.J., WAHLBERG, E., LEBOULCH, P. & CAO, Y. (2003). Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med., 9, 604-613.
13. CARMELIET, P. (2000). VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat. Med., 6, 1102-1103.
14. CLAUSS, M., GERLACH, M., GERLACH, H., BRETT, J., WANG, F., FAMILLETTI, P.C., PAN, Y.C., OLANDER, J.V., CONNOLLY, D.T. & STERN, D. (1990). Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med., 172, 1535-1545.
15. DOR, H.F., DJONOV, V., ABRAMOVITCH, R., ITIN, A., FISHMAN, G.I., CARMELIET, P., GOELMAN, G. & KESHET, E. (2002). Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J., 21, 1939-2947.
16. DVORAK, H.F. (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol., 20, 4368-4380.
17. ELSON, D.A., THURSTON, G., HUANG, L.E., GINZINGER, D.G., MCDONALD, D.M., JOHNSON, R.S. & ARBEIT, J.M. (2001). Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev., 15, 2520-2532.
18. EPSTEIN, S.E., KORNOWSKI, R., FUCHS, S. & DVORAK, H.F. (2001). Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation, 104, 115-119.
19. GUSSONI, E., BLAU, H.M. & KUNKEL, L.M. (1997). The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat. Med., 3, 970-977.
20. HACEIN-BEY-ABINA, S., VON KALLE, C., SCHMIDT, M., LE DEIST, F., WULFFRAAT, N., MCINTYRE, E., RADFORD, I., VILLEVAL, J.L., FRASER, C.C., CAVAZZANA-CALVO, M. & FISCHER, A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348, 255-256.
21. HASHIMOTO, G., INOKI, I., FUJII, Y., AOKI, T., IKEDA, E. & OKADA, Y. (2002). Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem., 277, 36288-36295.
22. HENRY, T.D., ANNEX, B.H., McKENDALL, G.R., AZRIN, M.A., LOPEZ, J.J., GIORDANO, F.J., SHAH, P.K., WILLERSON, J.T., BENZA, R.L., BERMAN, D.S., GIBSON, C.M., BAJAMONDE, A., RUNDLE, A.C., FINE, J. & McCLUSKEY, E.R. (2003). The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation, 107, 1359-1365.
23. ISNER, J.M. (2002). Myocardial gene therapy. Nature, 415, 234-239.
24. JAIN, R.K. (2003). Molecular regulation of vessel maturation. Nat. Med., 9, 685-693.
25. KHURANA, R. & SIMONS, M. (2003). Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc. Med., 13, 116-122.
26. KRINGSTEIN, A.M., ROSSI, F.M., HOFMANN, A. & BLAU, H.M. (1998). Graded transcriptional response to different concentrations of a single transactivator. Proc. Nall. Acad. Sci. U.S.A., 95, 13670-13675.
27. LEDERMAN, R.J., GUTTMAN, M.A., PETERS, D.C., THOMPSON, R.B., SORGER, J.M., DICK, A.J., RAMAN, V.K. & McVEIGH, E.R. (2002a). Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation, 105, 1282-1284.
28. LEDERMAN, R.J., MENDELSOHN, F.O., ANDERSON, R.D., SAUCEDO, J.F., TENAGLIA, A.N., HERMILLER, J.B., HILLEGASS, W.B., ROCHA-SINGH, K., MOON, T.E., WHITEHOUSE, M.J. & ANNEX, B.H. (2002b). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 359, 2053-2058.
29. LEE, R.J., SPRINGER, M.L., BLANCO-BOSE, W.E., SHAW, R., URSELL, P.C. & BLAU, H.M. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation, 102, 898-901.
30. LU, Y., SHANSKY, J., DEL TATTO, M., FERLAND, P., McGUIRE, S., MARSZALKOWSKI, J., MAISH, M., HOPKINS, R., WANG, X., KOSNIK, P., NACKMAN, M., LEE, A., CRESWICK, B. & VANDENBURGH, H. (2002). Therapeutic potential of implanted tissue-engineered bioartificial muscles delivering recombinant proteins to the sheep heart. Ann. N.Y. Acad. Sci., 961, 78-82.
31. LU, Y., SHANSKY, J., DEL TATTO, M., FERLAND, P., WANG, X. & VANDENBURGH, H. (2001). Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis. Circulation, 104, 594-599.
32. LUTTUN, A., TJWA, M., MOONS, L., WU, Y., ANGELILLO-SCHERRER, A., LIAO, F., NAGY, J.A., HOOPER, A., PRILLER, J., DE KLERCK, B., COMPERNOLLE, V., DACI, E., BOHLEN, P., DEWERCHIN, M., HERBERT, J.M., FAVA, R., MATTHYS, P., CARMELIET, G., COLLEN, D., DVORAK, H.F., HICKLIN, D.J. & CARMELIET, P. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med., 8, 831-840.
33. MAISONPIERRE, P.C., SURI, C., JONES, P.F., BARTUNKOVA, S., WIEGAND, S.J., RADZIEJEWSKI, C., COMPTON, D., McCLAIN, J., ALDRICH, T.H., PAPADOPOULOS, N., DALY, T.J., DAVIS, S., SATO, T.N. & YANCOPOULOS, G.D. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60.
34. MANDRIOTA, S.J. & PEPPER, M.S. (1998). Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res., 83, 852-859.
35. MASAKI, I., YONEMITSU, Y., YAMASHITA, A., SATA, S., TANII, M., KOMORI, K., NAKAGAWA, K., HOU, X., NAGAI, Y., HASEGAWA, M., SUGIMACHI, K. & SUEISHI, K. (2002). Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ. Res., 90, 966-973.
36. MENASCHE, P., HAGEGE, A.A., VILQUIN, J.T., DESNOS, M., ABERGEL, E., POUZET, B., BEL, A., SARATEANU, S., SCORSIN, M., SCHWARTZ, K., BRUNEVAL, P., BENBUNAN, M., MAROLLEAU, J.P. & DUBOC, D. (2003). Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol., 41, 1078-1083.
37. MOISSET, P.A., BONHAM, L., SKUK, D., KOEBERL, D., BRUSSEE, V., GOULET, M., ROY, B., ASSELIN, I., MILLER, A.D. & TREMBLAY, J.P. (2000). Systemic production of human granulocyte colony-stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts. Hum. Gene Ther., 11, 1277-1288.
38. MORIKAWA, S., BALUK, P., KAIDOH, T., HASKELL, A., JAIN, R.K. & McDONALD, D.M. (2002). Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol., 160, 985-1000.
39. NEHLS, V., DENZER, K. & DRENCKHAHN, D. (1992). Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res., 270, 469-474.
40. NEHLS, V., SCHUCHARDT, E. & DRENCKHAHN, D. (1994). The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc. Res., 48, 349-363.
41. NEUFELD, G., COHEN, T., GENGRINOVITCH, S. & POLTORAK, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13, 9-22.
42. PEAR, W.S., NOLAN, G.P., SCOTT, M.L. & BALTIMORE, D. (1993). Production of high-liter helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U.S.A., 90, 8392-8396.
43. REBAR, E.J., HUANG, Y., HICKEY, R., NATH, A.K., MEOLI, D., NATH, S., CHEN, B., XU, L., LIANG, Y., JAMIESON, A.C., ZHANG, L., SPRATT, S.K., CASE, C.C., WOLFFE, A. & GIORDANO, F.J. (2002). Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med., 8, 1427-1432.
44. RICHARDSON, T.P., PETERS, M.C., ENNETT, A.B. & MOONEY, D.J. (2001). Polymeric system for dual growth factor delivery. Nat. Biotechnol., 19, 1029-1034.
45. RISSANEN, T.T., MARKKANEN, J.E., ARVE, K., RUTANEN, J., KETTUNEN, M.I., VAJANTO, I., JAUHIAINEN, S., CASHION, L., GRUCHALA, M., NARVANEN, O., TAIPALE, P., KAUPPINEN, R.A., RUBANYI, G.M. & YLA-HERTTUALA, S. (2003). Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J., 17, 100-102.
46. SCHMIDT, M., CARBONARO, D.A., SPECKMANN, C., WISSLER, M., BOHNSACK, J., ELDER, M., ARONOW, B.J., NOLTA, J.A., KOHN, D.B. & VON KALLE, C. (2003). Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat. Med., 9, 463-468.
47. SCHWARZ, E.R., SPEAKMAN, M.T., PATTERSON, M., HALE, S.S., ISNER, J.M., KEDES, L.H. & KLONER, R.A. (2000). Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J. Am. Coll. Cardiol., 35, 1323-1330.
48. SIMONS, M., ANNEX, B.H., LAHAM, R.J., KLEIMAN, N., HENRY, T., DAUERMAN, H., UDELSON, J.E., GERVINO, E.V., PIKE, M., WHITEHOUSE, M.J., MOON, T. & CHRONOS, N.A. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation, 105, 788-793.
49. SPRINGER, M.L. & BLAU, H.M. (1997). High-efficiency retroviral infection of primary myoblasts. Somatic Cell Mol. Genet., 23, 203-209.
50. SPRINGER, M.L., CHEN, A.S., KRAFT, P.E., BEDNARSKI, M. & BLAU, H.M. (1998). VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell, 2, 549-558.
51. SPRINGER, M.L., OZAWA, C.R., BANFI, A., KRAFT, P.E., IP, T.K., BRAZELTON, T.R. & BLAU, H.M. (2003). Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. Mol. Ther., 7, 441-449.
52. ST GEORGE, J.A. (2003). Gene therapy progress and prospects: adenoviral vectors. Gene Ther., 10, 1135-1141.
53. SUNDBERG, C., NAGY, J.A., BROWN, L.F., FENG, D., ECKELHOEFER, I.A., MANSEAU, E.J., DVORAK, A.M. & DVORAK, H.F. (2001). Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am. J. Pathol., 158, 1145-1160.
54. SUZUKI, K., MURTUZA, B., SMOLENSKI, R.T., SAMMUT, I.A., SUZUKI, N., KANEDA, Y. & YACOUB, M.H. (2001). Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation, 104, I207-I212.
55. WANG, J.M., ZHENG, H., BLAIVAS, M. & KURACHI, K. (1997). Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood, 90, 1075-1082.
56. YLA-HERTTUALA, S. & ALITALO, K. (2003). Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med., 9, 694-701.
57. ZUCKER, S., MIRZA, H., CONNER, C.E., LORENZ, A.F., DREWS, M.H., BAHOU, W.F. & JESTY, J. (1998). Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int. J. Cancer, 75, 780-786.